TCON - Axsome's Alzheimer's Positive Results And Other News: The Good Bad And Ugly Of Biopharma
Axsome Therapeutics Reports Positive Alzheimer Results
Axsome Therapeutics Inc. (AXSM) reported that its lead drug candidate AXS 05 met its primary endpoint in the ADVANCE-1 Phase 2/3 trial. The ADVANCE-1 study was a randomized, double-blind, controlled, trial and had 366 patients suffering from Alzheimer’s disease. Currently, there is no FDA approved treatment in Alzheimer’s disease agitation, which is the most common form of dementia.
AXS-05 met the primary endpoint by showing a statistically significant mean reduction in the Cohen Mansfield Agitation Inventory ((CMAI)) total score compared to placebo at Week 5. The mean